Hypoimmunogenic Stem-Cell Islet Transplant Simulator

Type 1 diabetes cell therapy (as in Vertex's VX-880 iPSC-derived islet programme) still needs lifelong immunosuppression because allogeneic islets carry donor HLA molecules that a recipient's T cells recognise as foreign. Gene-editing the graft instead — knocking out HLA class I and II, then adding CD47 and PD-L1 as immune checkpoints — aims to make the cells invisible to rejection without suppressing the whole immune system. This simulator drops a 3D islet-cell cluster into a liver-sinusoid vessel alongside patrolling T cells and NK cells, runs a daily stochastic rejection model driven by whichever edits and immunosuppression level you choose, and tracks graft survival and insulin output over two simulated weeks of engraftment — showing why HLA-I knockout alone backfires (NK "missing-self" attack) unless CD47 is added alongside it.